• PharmaTutor
    26 April 2013

    PULSATILE DRUG DELIVERY SYSTEM AND RECENT ADVANCES: A REVIEW

    ABOUT AUTHORS:
    Bhaskar Ingole, Shradha Tiwari*
    SSS. Indira College of pharmacy,
    Vishnupuri, Nanded
    *Shraddha.life10@gmail.com

    ABSTRACT:
    Pulsatile drug delivery aims to release drugs on a programmed pattern means at appropriate time and/or at appropriate site of action. Pulsatile Drug Delivery Systems are gaining a lot of interest as they deliver the drug at the right place at the right time and in the right amount, thus providing spatial and temporal delivery and increasing patient compliance These systems are designed according to the circadian rhythm of the body. Pulsatile release of the drugs is used where a constant drug release is not desired.Gastric retentive systems, systems where the drug is released following a programmed lag phase, chronopharmaceutical drug delivery systems matching human circadian rhythms, multiunit or multilayer systems with various combinations of immediate and sustained-release preparation, are all classified under pulsatile drug delivery systems. On the other hand, site-controlled release is usually controlled by factors such as the pH of the target site, the enzymes present in the intestinal tract and the transit time/pressure of various parts of the intestine. In this review, recent patents on pulsatile drug delivery of oral dosage forms are summarized and discussed.

  • 26 April 2013
    AN OVERVIEW: AQUEOUS FILM COATING TECHNOLOGY ON TABLETS

    About Authors:
    Parmar Krutin D.1*, Pandya Kirtan B.2, Gajjar Alpesh M.3, Zala Shivraj D.3, Kela Amit N.1, Nathani Hitesh S.    1
    1*    C. U. Shah College of Pharmacy and Research, Wadhwan city, Surendranagar, Gujarat, India.
    2     Shree Balaji pharmacy college, Jaipur, Rajasthan, India.
    3    Shree V.B. Manvar college of pharmacy, Upleta, Gujarat, India.
    *krutinkp@gmail.com

    Abstract:
    Tablet coating is perhaps one of the oldest pharmaceutical processes still in existence. Earlier, Sugar coating was adopted for pharmaceutical as from confectionary industry. But as it was tedious process and required skilled manipulation, film coating was started to be preferred over sugar coating.  Development of film coating was mainly based on solutions of different polymers in various organic solvents. All these solvents are toxic in nature. Nobody ever was concerned about the problems like material cost, toxic effects due to coating or pollution etc. In today's competitive business environment, any cost saved will improve the market viability and success of any product. Therefore, left with no other choice but to eliminate the use of organic solvents and to start using water as the solvent system for tablet coating.
    The main focus of this review is, to study various aspects of aqueous based film coating.

    [adsense:336x280:8701650588]

  • 25 April 2013
    SUB-ACUTE HEPATO TOXICITY OF TAMOXIFEN CITRATE

    About Author:
    Zehira Nazir
    Master’s In Clinical Biochemistry
    University Of Kashmir
    zzehra275@gmail.com

  • 25 April 2013
    DEVELOPMENT AND VALIDATION OF FIRST ORDER DERIVATIVE METHOD FOR ANALYSIS OF EPERISONE HYDROCHLORIDE AND LORNOXICAM IN SYNTHETIC MIXTURE

    ABOUT AUTHORS:
    Harshil R. Patel*, Sejal K. Patel
    Department of Quality Assurance,
    S. K. Patel College of Pharmaceutical Education and Research,
    Ganpat University, Ganpat Vidyanagar – 384012, Mehsana, Gujarat, India.
    *harshil285@gmail.com

  • 24 April 2013
    ANTIOXIDANT AN OVERVIEW

    ABOUT AUTHORS:
    Sanjay Singh Bhandari *, Mahaveer Prasad Kabra, Raman Gupta, Ami Sharma
    Kota College of Pharmacy, SP-1, RIICO Industrial Area, Ranpur,
    Jhalawar road, Kota, Rajasthan, India – 324009
    *bhandarisanjay001@gmail.com

  • 24 April 2013
    ANALYTICAL METHOD DEVELOPMENT OF MONTELUKAST AND FEXOFINADINE COMBINATION IN PHARMACEUTICAL DOSAGE FORM BY USING HPLC METHOD

    ABOUT AUTHORS:
    Rituraj Singh Chundawat*, Yuvraj Singh Sarangdevot, Bhupendra Vyas, Gajendra Singh Rathore, Udaibhan Singh Rathore, Pankaj Sharma
    Department of Quality Assurance, Bhupal Nobles’ College of Pharmacy,
    Udaipur- 313002, Rajasthan, India
    *riturajsingh.chundawat@gmail.com

  • 23 April 2013
    REVIEW:- INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM

    ABOUT AUTHORS:
    1Abhijeet Welankiwar*, Sushant tope.
    1Government College of pharmacy
    kathora naka Amravati (Maharashtra) 444604.
    *abhi123welankiwar@gmail.com

  • 23 April 2013
    DEPRESSION AND COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS UNDERGOING HEMODIALYSIS

    ABOUT AUTHORS:
    Vishal V. Timaliya*, Prof.Mital v. Dalal
    Gujarat Technical University
    *vishal.vishal.timaniya@gmail.com

    ABSTRACT
    The main objectives of this study were the prevalence of depression and cognitive function impairments in patients undergoing hemodialysis.
    An observational study performed on 60 patients with CKD stage IV and V undergoing hemodialysis two or three times in a week and CKD stage I to III without hemodialysis. Depressive symptomatology, defined by a Center for Epidemiological Studies Depression Scale (CES-D) score of 16 or higher and cognitive function measured by Mini Mental State Examination (MMSE) questionnaire. All data was analyzed by MS excel and Graph pad Prism 5.0.

  • 22 April 2013
    INNOVATIVE NANOCRYSTAL TECHNOLOGY FOR POORLY WATER SOLUBLE DRUGS

    About Author:
    Dhananjay R. Abhang*, Sudhir S. Waghmode, Raju K.Hire, GangurdeA.B, Kasar S.A, Bairagi V.A
    K.B.H.S.S.Trust’s Institute of Pharmacy, Bhaygaon road,
    Malegaon camp, Malegaon,
    Dist: Nasik– 423 105, Maharashtra, India.
    *dhananjay.abhang@rediffmail.com

  • 22 April 2013
    TO ASSESS THE HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS

    About Author:
    Nishith Sheth
    M.Sc in Clinical Research
    Cranfield university
    sheth10687@gmail.com

    Abstract
    Osteoarthritis is one type of degenerative joint disease and also known as chronic musculoskeletal disease and it occurs mainly in elderly patients with the severe cause of disability. There are approximately 30 million persons affected with severe osteoarthritis and about 26 million persons are affected with severe osteoarthritis in United States only. The approximate annual cost to the public society in medical care is expected to reach 100 billion dollars by the end of 2020. From this much of cost, most of the cost is spent only in finding out the new diagnosis and treatment for this severe disease and also for the prevention of side effects. Today till 2010, 50% of the persons with the age over 75 suffer from the knee osteoarthritis. 80% of the aged persons with knee osteoarthritis feel difficulty in daily routine activities, while 20 % of the aged persons with mild osteoarthritis feel no difficulty in their daily routine activities.
    In this disorder, the joint loses the slippery cartilage those results from ‘wear and tear’ on a joint. Thus the joint becomes large, thick and painful. Thus the bone near the cartilage tries to change and produce overgrowth of the bone.  That’s why the tissue near the bone becomes inflamed and ligaments lose and joint muscle becomes weak. So the people with osteoarthritis feel pain when they are doing their normal routine activities.

Subscribe to Articles